APP and early-onset autosomal dominant Alzheimer disease: In contrast, PLG nanoconjugates, targeted with Angiopep-2, a ligand of the low-density lipoprotein receptor-related protein, show an increased passage across the BBB; in addition, the Angiopep-2-targeted genistein-PLG nanoconjugates accumulate in brain regions of APP/PS1 transgenic mice and exert therapeutic effects in this Alzheimer’s disease model [7].